Oxford Finance

From Wikipedia, the free encyclopedia

Oxford Finance Corporation provides debt financing to emerging life sciences companies worldwide. The company is often characterized as a "venture lender" due to its close collaboration with the venture capital community. Unlike most venture lenders that provide financing for both technology and life sciences companies, Oxford focuses exclusively on life sciences. Client specialties include pharmaceuticals, enabling technologies and tools, genomics and proteomics, medical devices and agricultural biotechnology. Oxford Finance Corporation is wholly owned subsidiary of the Sumitomo Corporation of America and is headquartered in Alexandria, Virginia.

Oxford Finance Corporation offers two principal loan products to its life science customers: equipment loans that are secured by a lien on specific equipment and other assets, and "all-asset" loans that provide unrestricted growth capital secured by a blanket lien on all of the assets of the borrower. Repayment tenors are typically in the three to four year range for both products. Oxford usually requires an "equity kicker" from borrowers in the form of warrants for common or preferred stock.

The President and Chief Executive Officer of Oxford Finance Corporation is J. Alden Philbrick IV, and Michael J. Altenburger is the Chief Financial Officer.